← Eichor
Condition: Rituximab Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Rituximab

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults
Phase 4 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT04518475Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Th
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07206823A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
Phase 3 · 31 location(s) · Cerium Pharmaceuticals, Inc. · NCT05696613Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Phase 2 · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT03986034Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)
Phase 2 · 2 location(s) · University of Utah · NCT06390956Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents
Phase 2/Phase 3 · 1 location(s) · Children's Cancer Group, China · NCT07168980Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
Phase 2 · 4 location(s) · Timothy Voorhees · NCT05786040Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
Phase 2 · 1 location(s) · Chinese PLA General Hospital · NCT06471738Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
Phase 1 · 55 location(s) · National Cancer Institute (NCI) · NCT04609046ZR2 Sequential Immunochemotherapy for Newly Treated MCL
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT05992597An Outcome Analysis of Primary Membranous Nephropathy
Phase N/A · 2 location(s) · Mario Negri Institute for Pharmacological Research · NCT06242327Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
Phase 2 · 1 location(s) · Ruijin Hospital · NCT07272499Selinexor in Combination With MTX+Ritu to Treat R/R CNSL
Phase 1/Phase 2 · 5 location(s) · Tong Chen, MD · NCT05698147Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thromb
Phase 3 · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT05338190A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compar
Phase 3 · 187 location(s) · BeOne Medicines · NCT06943872Belimumab After Rituximab in Resistant Primary Juvenile SS
Phase 4 · 1 location(s) · Peking Union Medical College Hospital · NCT06410833Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL
Phase 2 · 2 location(s) · Sun Yat-sen University · NCT06742502The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lympho
Phase 3 · 1 location(s) · Ruijin Hospital · NCT06522555Rituximab in Patients With ST-elevation Myocardial Infarction
Phase 2 · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT05211401Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, a
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07608978Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
Phase 2 · 92 location(s) · Novartis Pharmaceuticals · NCT06655896Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma
Phase 2 · 16 location(s) · Grupo Español de Linfomas y Transplante Autólogo de Médula Ó · NCT07285590Prevention of Epstein-Barr Virus Reactivation With the ATG-based Haploidentical Protocol Combined With Rituximab in Chil
NA · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT07693881Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy
Phase 3 · 1 location(s) · Amsterdam University Medical Center (UMC), Location Academic · NCT06714838CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07397832A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined
Phase 3 · 168 location(s) · Regeneron Pharmaceuticals · NCT06091865Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS
Phase 3 · 1 location(s) · Amsterdam UMC, location VUmc · NCT05834855The Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCT
Phase 2 · 1 location(s) · Anhui Provincial Hospital · NCT06362967Epcoritamab and Rituximab for First-line Follicular Lymphoma
Phase 2 · 6 location(s) · Reid Merryman, MD · NCT05783609Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial
Phase N/A · 26 location(s) · Fondazione Italiana Linfomi - ETS · NCT05816850
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.